Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 18/20 | 0.91 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | ESR1 | P03372 | 8/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.72 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.62 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764036 | 0.95 | ESRRG (1.00) | ESRRGTP53MAPTESR1ESR2 | |
| SCHEMBL20764079 | 0.89 | ESRRG (1.00) | ESRRGTP53MAPTESR1ESR2 | |
| SCHEMBL20746251 | 0.87 | ESRRG (1.00) | ESRRGTP53MAPTESR1ESR2 | |
| SCHEMBL20764002 | 0.86 | ESRRG (1.00) | ESRRGTP53MAPTESR1ESR2 | |
| SCHEMBL22311183 | 0.85 | ESRRG (1.00) | ESRRGTP53MAPTESR1ESR2 | |
| SCHEMBL31337398 | 0.84 | NPC1 (0.81) | ESRRGTP53MAPTESR1ESR2 | |
| SCHEMBL20764231 | 0.84 | ESRRG (1.00) | ESRRGTP53MAPTESR1ESR2 | |
| SCHEMBL20764280 | 0.83 | ESRRG (1.00) | ESRRGTP53MAPTESR1ESR2 | |
| SCHEMBL20764088 | 0.82 | ESRRG (0.76) | ESRRGTP53MAPTESR1ESR2 | |
| SCHEMBL20764258 | 0.82 | ESRRG (0.80) | ESRRGTP53MAPTESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795162-B2 | Modulators of the estrogen-related receptor | SAINT LOUIS UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| US-20200247792-A1 | ERR INVERSE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2019036562-A1 | ERR INVERSE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247792-A1 | ERR INVERSE AGONISTS | ESRRA, ESRRB, ESR2 | ESRRG 4/4885TP53 2879/4885MAPT 3634/4885 |
| US-11795162-B2 | Modulators of the estrogen-related receptor | ESR2, GPER1, ESRRG | ESRRG 3/4885TP53 3812/4885MAPT 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.